Navigation Links
Rosemary chicken protects your brain from free radicals
Date:10/30/2007

Rosemary not only tastes good in culinary dishes such as Rosemary chicken and lamb, but scientists have now found it is also good for your brain. A collaborative group from the Burnham Institute for Medical Research (Burnham Institute) in La Jolla, CA and in Japan, report that the herb rosemary contains an ingredient that fights off free radical damage in the brain. The active ingredient in rosemary, known as carnosic acid (CA), can protect the brain from stroke and neurodegeneration that is due to injurious chemical free radicals. These radicals are thought to contribute not only to stroke and neurodegenerative conditions such as Alzheimers, but also to the ill effects of normal aging on the brain.

In two expedited publications by The Journal of Neurochemistry and Nature Reviews Neuroscience, the scientists report for the first time that CA activates a novel signaling pathway that protects brain cells from the ravages of free radicals. In animal models, the scientific group, led by Drs. Takumi Satoh (Iwate University, Japan) and Stuart Lipton (Burnham Institute), found that CA becomes activated by the free radical damage itself, remaining innocuous unless needed, exactly what is wanted in a drug. The scientists call this type of action a pathological-activated therapeutic or PAT drug. A pat represents a gentle tap and not the heavy sledge hammer that some drugs produce, including significant side effects in areas of the body where their effects are not needed and not wanted.

This new type of drug works through a mechanism known as redox chemistry in which electrons are transferred from one molecule to another in order to activate the bodys own defense system, said Stuart A. Lipton, MD, PhD, the senior author on the paper and Director, Professor, and Senior Vice President at the Burnhams Del E. Webb Neuroscience, Aging, and Stem Cell Research Center. Moreover, unlike most new drugs, this type of compound may well be safe and clinically tolerated because it is present in a naturally-occurring herb that is known to get into the brain and has been consumed by people for over a thousand years. Dr. Lipton is also a practicing neurologist at the University of California, San Diego, and therefore knows first-hand that such drugs are critically needed for care of the aging and neurologically-ill patients.

Rosemary is a shrubby evergreen bush and, according to folklore, takes its name from the Virgin Mary, who draped her cloak on the bush, placing a white flower on top of the cloak. By the following morning, the flower had turned blue, and thereafter the plant was known as the Rose of Mary. Rosemary, grown in the Alps since the Middle Ages, has became part of European folk medicine, and was thought to help the nervous system and ward off sickness. Until now, however, the exact chemical pathways involved in its beneficial effects have remained unknown. Additionally, the new scientific work, identifying the compound in rosemary that is beneficial, should allow even better and more effective drugs in this class to be developed in the near future. Along these lines, Satoh and Lipton have filed a United States patent application for a whole series of novel compounds that show increased benefits over rosemary itself. This is not to say that Rosemary chicken is not good for you, said Dr. Satoh, but it means that we can do even better in protecting the brain from terrible disorders such as Alzheimers and Lou Gehrigs disease, perhaps even slowing down the effects of normal aging, by developing new and improved cousins to the active ingredient in rosemary. The authors hope that such drugs can be developed for people over the next few years.


'/>"/>

Contact: Andrea Moser
amoser@burnham.org
858-646-3146
Burnham Institute
Source:Eurekalert

Related biology news :

1. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
2. What comes first…the chicken, the egg, or the bad attitude?
3. Hospitalizations because of chicken pox down dramatically since implementation of vaccine
4. Geoscientists follow arsenic from chicken feed to streambeds
5. UF scientists restore sight to chickens with blinding disease
6. Origen publishes in Nature a robust and versatile method for creating transgenic chickens
7. Arsenic in chicken feed may pose health risks to humans, C&EN reports
8. Bound for destruction: Ubiquitination protects against improper Notch signaling
9. Experiments provide proof of how traveling in groups protects insects
10. Experiments provide proof of how traveling in groups protects insects
11. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology: